Full Press Release Details
SAN FRANCISCO and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate at the following investor conferences.
Jefferies Global Healthcare ConferenceDate: Wednesday, June 3, 2026Fireside Time: 11:40 a.m. ET
Goldman Sachs 47thAnnual Global Healthcare ConferenceDate: Wednesday, June 10, 2026Fireside Time: 9:20 a.m. ET
A live and archived webcast of the fireside chats will be available via theNews & Eventspage in the Investors section of the Apogee Therapeutics website.
About ApogeeApogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, EoE, Chronic Obstructive Pulmonary Disease (COPD) and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Zumilokibart, the company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets, as well as asthma and EoE. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visithttps://apogeetherapeutics.com.